New drug for treatment of resistant tuberculosis presented in Russia

12 April 2017

A new drug for the treatment of resistant tuberculosis has been recently presented in Russia, according to recent statements of the press-service of the Russian Ministry of Health.

To date, the drug has successfully passed clinical testing, while its serious production will be started next year, reports The Pharma Letter’s local correspondent.

The new drug will be produced by Infectex,a portfolio company of Maxwell Biotech Venture Fund (MBVF)and one of Russia’s leading biotech companies. Russian registration for the drug has been started, and it is planned that the new substance will go on sale in 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK